摘要
目的比较FOLFOX4与XELOX方案治疗晚期结直肠癌的近期疗效和毒副反应。方法 56例晚期结直肠癌患者随机分为2组,FOLFOX4组28例,XELOX组28例,2组均化疗4个周期以上。按WHO标准评价客观疗效和不良反应。结果 56例患者中有2例因不能耐受不良反应而放弃,均为FOLFOX4组,余54例均可评价疗效,其中FOLFOX4组:完全缓解(CR)3例,部分缓解(PR)9例,稳定(SD)11例,进展(PD)3例,总有效率(RR)46.2%。XELOX组:CR 2例,PR 10例,SD 11例,PD 5例,RR 42.9%,两组近期有效率无明显统计学差异。不良反应比较,手足综合征以XELOX组显著(P<0.05),Ⅲ～Ⅳ级恶心呕吐发生率FOLFOX4组较高(P<0.05),余不良反应均无明显统计学差异。结论 FOLFOX4与XELOX方案相比在近期疗效上无明显差异,但XELOX组不良反应较低,耐受性较好。
Objective To evaluate the clinical efficacy and toxicity of FOLFOX4 versus XELOX in the treatment of advanced colorectal cancer.Methods Fifty-six cases with advanced colorectal cancer were enrolled into this study.They were randomly but equally divided into FOLFOX4 group and XELOX group respectively.All patients received more than four cycles of chemotherapy.The efficacy and toxicity were evaluated according to WHO standard.Results Fifty-four cases were available for objective response,2 cases were abandoned for not tolerating toxicity in FOLFOX4 group.The overall response rate was 46.2%（CR3,PR9） in FOLFOX group and 42.9%（CR2,PR10） in XELOX group.The difference in response rate was not statistically significant between the two groups（P0.05）.The incidence of grade Ⅲ～Ⅳ nausea and vomiting was significantly lower in XELOX group than in FOLFOX4 group（P0.05）,but hand and foot syndrome in XELOX group were more obvious than in FOLFOX4 group（P0.05）,and no other statistical significance existed（P0.05）.Conclusion The difference in response rate was not statistically significant between the two groups,XELOX regimen may be safer than FOLFOX4 regimen.
出处
《实用临床医药杂志》
CAS
2011年第15期43-45,共3页
Journal of Clinical Medicine in Practice
